Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: Does effectiveness offset the teratogenic risks?
antiseizure medication
levetiracetam
monotherapy
reproductive age
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
09
01
2024
received:
31
10
2023
accepted:
09
01
2024
pubmed:
31
1
2024
medline:
31
1
2024
entrez:
31
1
2024
Statut:
ppublish
Résumé
Regulatory agencies have recently discouraged the prescription of topiramate (TPM) to women of childbearing potential with epilepsy due to growing evidence of the teratogenic and neurodevelopmental risks associated with its use during pregnancy. It remains, however, unclear whether the use of TPM in this population can be supported to some extent by its high effectiveness. In this multicenter, retrospective, cohort study performed at 22 epilepsy centers, we investigated the comparative effectiveness of TPM and levetiracetam (LEV) given as first-line antiseizure medication in a cohort of women of childbearing potential with idiopathic generalized epilepsy (IGE). A total of 336 participants were included, of whom 24 (7.1%) received TPM and 312 (92.9%) LEV. Women treated with TPM had significantly higher risks of treatment failure and treatment withdrawal and were less likely to achieve seizure freedom at 12 months compared to women treated with LEV. In conclusion, this study highlighted a low tendency among clinicians to use TPM in women of childbearing potential with IGE, anticipating the recently released restrictions on its use. Furthermore, the available data on effectiveness do not appear to support the use of TPM in this population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27-e34Investigateurs
Daniela Fatuzzo
(D)
Giulio Pastorelli
(G)
Eleonora Rosati
(E)
Biagio Sancetta
(B)
Pierpaolo Quarato
(P)
Alessandra Morano
(A)
Enrico Salamone
(E)
Alessio Petrungaro
(A)
Emanuela Viglietta
(E)
Pietro Pignatta
(P)
Vittoria Cianci
(V)
Irene Bagnasco
(I)
Edoardo Pronello
(E)
Marta Piccioli
(M)
Chiara Milano
(C)
Domenica Battaglia
(D)
Marco Perulli
(M)
Francesca Bisulli
(F)
Martina Fanella
(M)
Roberto De Simone
(R)
Giuseppe Pontrelli
(G)
Giovanni Boero
(G)
Francesca Gilio
(F)
Francesca Gragnani
(F)
Carla Marini
(C)
Sara Gasparini
(S)
Informations de copyright
© 2024 International League Against Epilepsy.
Références
Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of Prenatal Exposure to antiseizure medication with risk of autism and intellectual disability [published correction appears in JAMA neurol. 2022 Jul 1;79(7):727]. JAMA Neurol. 2022;79(7):672-681. https://doi.org/10.1001/jamaneurol.2022.1269
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538. https://doi.org/10.1016/S1474-4422(18)30107-8
Cerulli Irelli E, Cocchi E, Morano A, Casciato S, Fanella M, Albini M, et al. Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy. J Neurol Sci. 2020;415:116940. https://doi.org/10.1016/j.jns.2020.116940
Angus-Leppan H, Shankar R, Cock H. Royal College of psychiatrists intellectual disability section, the United Kingdom learning disability professional senate, and 62 signatories. Valproate, women, and exceptional circumstances. BMJ. 2018;362:k3625. https://doi.org/10.1136/bmj.k3625
Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56(7):1006-1019. https://doi.org/10.1111/epi.13021
European Medicines Agency. Assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. 2023. Available at: https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-prac-recommends-new-measures-avoid-topiramate-exposure-pregnancy_en.pdf Accessed September 27, 2023.
Cohen JM, Alvestad S, Cesta CE, Bjørk MH, Leinonen MK, Nørgaard M, et al. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol. 2023;93(3):551-562. https://doi.org/10.1002/ana.26561
Hernández-Díaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21-28. https://doi.org/10.1097/AOG.0000000000000018
Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, et al. Levetiracetam vs lamotrigine as first-line antiseizure medication in female patients with idiopathic generalized epilepsy. JAMA Neurol. 2023;80:1174-1181. https://doi.org/10.1001/jamaneurol.2023.3400
Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1475-1499. https://doi.org/10.1111/epi.17236
Stevelink R, Al-Toma D, Jansen FE, Lamberink HJ, Asadi-Pooya AA, Farazdaghi M, et al. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: a systematic review and individual participant data meta-analysis. EClinicalMedicine. 2022;53:101732. https://doi.org/10.1016/j.eclinm.2022.101732
Gomez-Ibañez A, McLachlan RS, Mirsattari SM, Diosy DC, Burneo JG. Prognostic factors in patients with refractory idiopathic generalized epilepsy. Epilepsy Res. 2017;130:69-73. https://doi.org/10.1016/j.eplepsyres.2017.01.011
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology. 2019;93(9):e831-e840. https://doi.org/10.1212/WNL.0000000000008001
French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia. 2002;43(Suppl 10):3-27. https://doi.org/10.1046/j.1528-1157.43.s.10.1.x
Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology. 2008;71(4):272-276. https://doi.org/10.1212/01.wnl.0000318293.28278.33
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016-1026. https://doi.org/10.1016/S0140-6736(07)60461-9
Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC study group [published correction appears in neurology 1999 Sep 22;53(5):1162]. Neurology. 1999;52(7):1330-1337. https://doi.org/10.1212/wnl.52.7.1330
Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Ther Adv Drug Saf. 2012;3(6):279-289. https://doi.org/10.1177/2042098612455357
Sarayani A, Winterstein A, Cristofoletti R, Vozmediano V, Schmidt S, Brown J. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. Contraception. 2023;120:109953. https://doi.org/10.1016/j.contraception.2023.109953